ARTICLE | Clinical News
Oral neratinib regulatory update
September 26, 2016 7:00 AM UTC
FDA accepted for review an NDA from Puma for oral neratinib as an extended adjuvant treatment for early stage HER2-amplified breast cancer in patients previously treated with Herceptin trastuzumab. T...